Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.66 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL226465 | 0.83 | UBE2T (0.70) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19372016 | 0.83 | UBE2T (0.70) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| Bromide SCHEMBL7601035 | 0.81 | UBE2T (0.68) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5401254 | 0.80 | MAPT (0.58) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL244156 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL16397518 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| Fluoride SCHEMBL7600822 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL244157 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2791997 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2205875 | 0.79 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412328-B1 | DOLASTATIN 10 DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | claimed |
| EP-1435352-A2 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | Wyeth Holdings Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| US-6737409-B2 | FOR CANCER THERAPY | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | claimed |
| EP-1412328-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-28 | — | — | EP | claimed |
| US-20030055002-A1 | Dolastatin 10 derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | claimed |
| WO-2003008378-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | claimed |
| EP-0582789-B1 | Novel 7-(substituted)-8-(substituted)-9-(substituted glycyl)amido-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 2001-10-04 | — | — | EP | claimed |
| EP-0582829-B1 | 9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines as antibiotic agents | AMERICAN CYANAMID CO (US) | 2001-09-12 | — | — | EP | claimed |
| EP-0582788-B1 | 7-(Substituted)-9- (substituted glycyl)-amido)-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID CO (US) | 1998-07-29 | — | — | EP | claimed |
| US-5567692-A | CONTROLLING BACTERIA INFECTIONS | AMERICAN CYANAMID COMPANY (US) | 1996-10-22 | — | — | US | claimed |
| US-5495031-A | Process for the production of 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1996-02-27 | — | — | US | claimed |
| US-5466684-A | 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1995-11-14 | — | — | US | claimed |
| US-5442059-A | Antibiotics for mammalian and veterninary diseases | AMERICAN CYANAMID COMPANY (US) | 1995-08-15 | — | — | US | claimed |
| US-5420272-A | 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1995-05-30 | — | — | US | claimed |
| EP-0618190-A1 | 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-10-05 | — | — | EP | claimed |
| US-5328902-A | Antibiotics | AMERICAN CYANAMID CO. (US) | 1994-07-12 | — | — | US | claimed |
| EP-0582789-A1 | Novel 7-(substituted)-8-(substituted)-9- (substituted glycyl)amido -6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-02-16 | — | — | EP | claimed |
| EP-0582788-A1 | 7-(Substituted)-9- (substituted glycyl)-amido)-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-02-16 | — | — | EP | claimed |
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| EP-0582788-A1 | 7-(Substituted)-9- (substituted glycyl)-amido)-6-demethyl-6-deoxytetracyclines | AMERICAN CYANAMID COMPANY (US) | 1994-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055002-A1 | Dolastatin 10 derivatives | DAD1, DDOST, NPC1 | UBE2T 4333/4885ASIC3 3814/4885SMN1; SMN2 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.